Prevalence of PD-L1 Expression in Non-Small Cell Lung Cancer: a Real-World Australian Perspective

被引：0
|
作者：
Prabhakaran, S. [1 ]
Russell, P. A. [2 ,3 ]
Farrall, A. L. [1 ]
Asadi, K. [4 ]
Barrett, W. [5 ]
Cooper, C. [6 ]
Cooper, W. [7 ]
Duhig, E. E. [8 ]
Egan, M. [9 ]
Fox, S. [10 ]
Godbolt, D. [11 ,12 ]
Gupta, S. [13 ]
Cotton, S. [14 ]
Leslie, C. [15 ]
Leong, T. [16 ]
Moffat, D. [17 ]
Qiu, M. [5 ]
Sivasubramaniam, V. [18 ]
Snell, C. [19 ]
Skerman, J. [20 ]
Walsh, M. [21 ]
Whale, K. [22 ]
Klebe, S. [17 ]
机构：
[1] Flinders Univ S Australia, Adelaide, SA, Australia
[2] St Vincents Hosp, Dept Anat Pathol, Melbourne, Vic, Australia
[3] Univ Melbourne, Melbourne, Vic, Australia
[4] Austin Hlth, Dept Gastroenterol & Hepatol, Melbourne, Vic, Australia
[5] SydPath St Vincents Hosp, Sydney, NSW, Australia
[6] Princess Alexandra Hosp, Pathol Queensland, Brisbane, Qld, Australia
[7] NSW Hlth Pathol Cent Sydney RPAH, Sydney, NSW, Australia
[8] Sullivan Nicolaides Pathol, Brisbane, Qld, Australia
[9] St Vincents Hosp, Melbourne, Vic, Australia
[10] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[11] Prince Charles Hosp, Pathol Queensland, Brisbane, Qld, Australia
[12] Princess Alexandra Hosp, Brisbane, Qld, Australia
[13] Prince Charles Hosp, Pathol Queensland, Brisbane, Qld, Australia
[14] Royal Hobart Hospita, PathSouth, Antat Pathol, Hobart, Tas, Australia
[15] QEII, PathWest, Perth, WA, Australia
[16] St Vincents Hosp Melbourne, Melbourne, Vic, Australia
[17] SA Pathology, Adelaide, SA, Australia
[18] SydPath St Vincents Hosp Sydney, Sydney, NSW, Australia
[19] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[20] Pathol Queensland, Brisbane, Qld, Australia
[21] Sullivan Nicolaides Pathol, Brisbane, Qld, Australia
[22] PathSouth, Antat Pathol, Hobart, Tas, Australia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
PD-L1; non-small cell lung cancer; immunotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP06.02-01
引用
收藏
页码：S479 / S479
页数：1
相关论文
共 50 条
  • [41] Lower prevalence of PD-L1 expression in advanced non-small lung cancer in Brazil.
    Gelatti, Ana Caroline
    Moura, Fernando
    Gaiger, Ana Maria Franco
    de Macedo, Mariana Petaccia
    Lopes, Lisandro Ferreira
    Zaffaroni, Facundo
    Cordeiro De Lima, Vladmir Claudio
    Werutsky, Gustavo
    Araujo, Luiz H.
    Mascarenhas, Samira
    Mathias, Clarissa
    Shiang, Christina
    Viola, Patricia Pacheco
    Zukin, Mauro
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer
    Dori, Shani Ben
    Aizic, Asaf
    Sabo, Edmond
    Hershkovitz, Dov
    LUNG CANCER, 2020, 147 : 91 - 98
  • [43] Real-world treatment patterns and outcomes in PD-L1-positive non-small cell lung cancer
    Zhang, Xinke
    DeClue, Richard W.
    Herms, Lisa
    Yang, Mo
    Pawar, Vivek
    Masters, Elizabeth T.
    Ruisi, Mary
    Chin, Kevin
    Velcheti, Vamsidhar
    IMMUNOTHERAPY, 2021, 13 (18) : 1521 - 1533
  • [44] Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China
    Sheng, Jiamin
    Li, Hui
    Yu, Xiaoqing
    Yu, Sizhe
    Chen, Kaiyan
    Pan, Guoqiang
    Xie, Mingying
    Li, Na
    Zhou, Zichao
    Fan, Yun
    THORACIC CANCER, 2021, 12 (22) : 3019 - 3031
  • [45] Regulation of PD-L1 expression in non-small cell lung cancer by interleukin-1β
    Hirayama, Aiko
    Tanaka, Kentaro
    Tsutsumi, Hirono
    Nakanishi, Takayuki
    Yamashita, Sho
    Mizusaki, Shun
    Ishii, Yumiko
    Ota, Keiichi
    Yoneshima, Yasuto
    Iwama, Eiji
    Okamoto, Isamu
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [46] Author Correction: Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors
    Peng Song
    Jingcheng Zhang
    Congcong Shang
    Li Zhang
    Scientific Reports, 10
  • [47] Real-world experience with anti-PD-1/PD-L1 monotherapy in patients with non-small cell lung cancer A retrospective Austrian multicenter study
    Geiger-Gritsch, Sabine
    Olschewski, Horst
    Kocher, Florian
    Wurm, Robert
    Absenger, Gudrun
    Flicker, Martin
    Hermann, Andre
    Heininger, Peter
    Fiegl, Michael
    Zechmeister, Melanie
    Endel, Florian
    Wild, Claudia
    Pall, Georg
    WIENER KLINISCHE WOCHENSCHRIFT, 2021, 133 (21-22) : 1122 - 1130
  • [48] Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients
    Ruiz, Gonzalo
    Enrico, Diego
    Mahmoud, Yamil D.
    Ruiz, Alan
    Cantarella, Maria Florencia
    Leguina, Laura
    Barberis, Mariana
    Bena, Asuncion
    Brest, Esteban
    Starapoli, Solange
    Bertelli, Andrea Mendoza
    Tsou, Florencia
    Pupareli, Carmen
    Coppola, Maria Pia
    Scocimarro, Alejandra
    Sena, Susana
    Levit, Patricio
    Perfetti, Aldo
    Aman, Enrique
    Girotti, Maria Romina
    Arrieta, Oscar
    Martin, Claudio
    Salanova, Ruben
    THORACIC CANCER, 2024, 15 (11) : 895 - 905
  • [49] PREDICTORS OF PD-L1 TESTING IN NON-SMALL CELL LUNG CANCER
    DiBonaventura, M.
    Meyers, A.
    Higginbottom, K.
    Morimoto, Y.
    Ilacqua, J.
    VALUE IN HEALTH, 2016, 19 (07) : A763 - A763
  • [50] Frontline pembrolizumab monotherapy for metastatic non-small cell lung cancer with PD-L1 expression ≥50%: real-world outcomes in a US community oncology setting
    Gadgeel, Shirish M.
    Rai, Pragya
    Annavarapu, Srinivas
    Alam, Sartaj
    Goldschmidt, Jerome H.
    West, Howard
    Santorelli, Melissa
    Martins, Renata Eiras
    FRONTIERS IN ONCOLOGY, 2024, 14
12345